Topics

Clinical Trials About "Mylan announces voluntary recall Alprazolam tablets" RSS

03:33 EST 15th December 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Mylan announces voluntary recall Alprazolam tablets" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Mylan announces voluntary recall Alprazolam tablets" on BioPortfolio

We have published hundreds of Mylan announces voluntary recall Alprazolam tablets news stories on BioPortfolio along with dozens of Mylan announces voluntary recall Alprazolam tablets Clinical Trials and PubMed Articles about Mylan announces voluntary recall Alprazolam tablets for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mylan announces voluntary recall Alprazolam tablets Companies in our database. You can also find out about relevant Mylan announces voluntary recall Alprazolam tablets Drugs and Medications on this site too.

Showing "Mylan announces voluntary recall Alprazolam tablets" Clinical Trials 1–25 of 2,700+

Extremely Relevant

Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

The objective of this study was to investigate the bioequivalence of Mylan's alprazolam 3 mg Extended-release tablets to Pharmacia & Upjohn's Xanax XR® 3 mg tablets following a single, oral 3 mg (1 x 3 mg) dose administered under fasting conditions.


Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets

The objective of the study is to demonstrate the bioequivalence (BE) of two alprazolam 1 mg tablets.

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

To demonstrate the relative bioavailability of Alprazolam tablets, 1 mg.


Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA with that of 3 mg XANAX XR® Tablets by Pharmacia & Upjohn Company following a single oral dose (1 x 3 mg extended release tablet) in healthy adult subjects administered under non-fasting conditions.

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA with that of 3 mg XANAX XR® Tablets by Pharmacia & Upjohn Company following a single oral dose (1 x 3 mg extended release tablet) in healthy adult subjects administered under fasting conditions.

A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions

The purpose of this study is to compare bioavailability between formulations of alprazolam in tablets to determine their bioequivalence in terms of rate and magnitude of absorption.

A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety

This was a multicenter, open-label, randomized crossover trial comparing two treatments, Alprazolam ODT versus conventional alprazolam tablets, in subjects who were already taking conventional immediate-release alprazolam tablets for anxiety. The trial included five study visits (four periods of 7 3 -day duration): Screening (Visit 1), Treatment Period 1 (Visit 2), Treatment Period 2 (Visit 3), Final Visit (Visit 4), and Follow-up (Visit 5 [telephone visit]). At Visit 1, f...

Bioequivalence of Alprazolam Sublingual vs Oral Tablets

This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from a standard orally administered tablet.

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg.

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia & Upjohn Company following a single oral dose (1 x 3 mg extended-release tablet) in healthy adult volunteers administrated under fasting conditions.

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-Fasting Conditions

The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia & Upjohn Company following a single oral dose (1 x 3 mg extended-release tablet) in healthy adult volunteers administrated under non-fasting conditions.

Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions

The objective of the study is to demonstrate the bioequivalence (BE) of alprazolam 1 mg tablet with Xanax® 1 mg tablet under fed conditions.

Relevant

Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg

The objective of this study was to investigate the bioequivalence of Mylan's glimepiride 1 mg tablets to Aventis Amaryl® 1 mg tablets following a single, oral 1 mg (1 x 1 mg) dose administered under fed conditions.

Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg

The objective of this study was to investigate the bioequivalence of Mylan pioglitazone HCl 45 mg tablets to Takeda Actos® 45 mg tablets following a single, oral 45 mg (1 x 45 mg) dose administration under fed conditions.

Food Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

The objective of this study was to investigate the bioequivalence of Mylan's midodrine HCl 5 mg tablets to Roberts ProAmatine® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administration under fed conditions.

Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose administered under fed conditions.

Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg

The objective of this study was to investigate the bioequivalence of Mylan's lamotrigine 25 mg tablets to GlaxoSmithKline's (GSK) Lamictal® 25 mg tablets following a single, oral 50 mg (2 x 25 mg) dose administration under fed conditions.

Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

The objective of this study was to investigate the bioequivalence of Mylan's midodrine HCl 5 mg tablets to Roberts ProAmatine® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administration under fed conditions.

Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

The objective of this study was to investigate the bioequivalence of Mylan's azithromycin 600 mg tablets to Pfizer's Zithromax® 600 mg tablets following a single, oral 600 mg (1 x 600 mg) dose administered under fed conditions.

Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

The objective of this study was to investigate the bioequivalence of Mylan's carvedilol 12.5 mg tablets to GSK's Coreg® 12.5 mg tablets following a single, oral 12.5 mg (1 x 12.5 mg) dose administered under fed conditions.

Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg

The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg) dose administration under fasting conditions.

Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg

The objective of this study was to investigate the bioequivalence of Mylan's hydrochlorothiazide 50 mg tablets to Ivax's Hydrochlorothiazide 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.

Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment

The purpose of this study is to determine whether the combination of aerobic physical exercise and alprazolam in patients with panic disorder has a better therapeutic response than the treatment with alprazolam alone.

Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg

The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 200 μg tablets to Abbott's Synthroid® 200 μg tablets following a single 600 μg (3 x 200 μg) dose administration in healthy volunteers under fasting conditions. Twenty-nine healthy, non-smoking, subjects between the ages of 18 and 47 completed this open-label, randomized, two-period, two-treatment, single-dose crossover study conducted by Dr. James D. Carlson at PRACS Institut...

Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

The objective of this study was to investigate the bioequivalence of Mylan midodrine HCl 5 mg tablets to Roberts ProAmatine® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administration under fasting conditions.


More From BioPortfolio on "Mylan announces voluntary recall Alprazolam tablets"

Quick Search